Publication|Articles|February 18, 2026
- Pharmaceutical Executive: February 2026
- Volume 46
- Issue 1
Pharmaceutical Executive: February 2026 Interactive Digital Edition
View the Pharmaceutical Executive February 2026 issue in an interactive format.
Advertisement
Click
Articles in this issue
4 months ago
A New Pharma Playbook4 months ago
When Friction Meets Force in Clinical Research4 months ago
Today’s China Crucible: What It Means for Pharma5 months ago
Taking Advantage of ‘Hidden Gem’ Talent Hubs5 months ago
To Build or to Buy: Determining Your AI PathAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer
2
The Rise of Direct-to-Patient Models in Pharma: Opportunities and Risks in Bypassing Traditional Distribution Channels
3
Novartis Announces $105 Million Collaborative Agreement with Antares Therapeutics
4
Ibrance Wins FDA Approval for HR-Positive, HER2-Positive Metastatic Breast Cancer Maintenance Therapy
5